Dengue Burden and Expert Calls
In 2023, India grappled with an alarming number of dengue cases, exceeding 2.89 lakh, though the true extent is likely underestimated due to reporting
limitations. This situation has spurred a critical dialogue among public health specialists, scientists, and policymakers. They convened in New Delhi to discuss pressing needs, particularly the strengthening of diagnostic capabilities and vaccine deployment to combat the escalating threat of dengue. This gathering is particularly timely as it precedes the monsoon season, a period notorious for increased Aedes aegypti mosquito activity and subsequent dengue transmission across South and Southeast Asia. Dr. Catharina Boehme of the WHO South-East Asia Regional Office underscored the region's vulnerability, noting it accounts for over half of the global dengue burden and puts 1.3 billion people at risk across ten endemic nations. She articulated that the rising tide of dengue is not merely a health crisis but also an economic and social one, leading to lost productivity and diminished futures.
India's Progress and Hurdles
India has declared dengue a top national health priority, demonstrating progress on several fronts. Scientist Taruna Madan Gupta from ICMR highlighted advancements in public health infrastructure and the fostering of public-private collaborations. A significant development is the ongoing Phase III trials for an indigenous tetravalent dengue vaccine, involving over 10,000 participants, alongside regulatory advancements for global vaccines. Despite these strides, a crucial gap persists: the absence of a specific and effective therapeutic treatment for dengue. Experts acknowledge improvements in surveillance and scientific understanding, yet patients still lack direct treatment options. Dr. Sanjay Sarin of DNDi emphasized that closing this therapeutic gap necessitates unwavering commitment from governments, funding bodies, and international partners to ensure better patient outcomes and control the disease's spread.
Understanding Dengue Fever
Dengue fever is a viral illness transmitted by the Aedes mosquito, a vector primarily active during daylight hours. While often presenting with mild or asymptomatic symptoms, dengue can, in some instances, lead to severe illness requiring hospitalization and potentially proving fatal. Typical manifestations include a sudden high fever, intense headaches, and significant pain in muscles, joints, or bones. A characteristic skin rash frequently appears a few days after the fever onset. Other symptoms can involve nausea, vomiting, and profound fatigue. The World Health Organization (WHO) estimates that approximately half of the global population is currently susceptible to dengue, with around 390 million infections occurring annually and nearly 100 million individuals experiencing symptoms each year. Two principal authorized vaccines globally, Dengvaxia and Qdenga, are available and aim to provide protection against all four dengue virus serotypes, with a key focus on mitigating severe disease and reducing hospitalizations.
